Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Taysha Gene Therapies's enterprise value is $1,236.99 Mil.
Taysha Gene Therapies's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-148.42 Mil. Therefore, Taysha Gene Therapies's EV-to-EBITDA for today is -8.33.
The historical rank and industry rank for Taysha Gene Therapies's EV-to-EBITDA or its related term are showing as below:
TSHA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -37.37 Med: -4.93 Max: -0.07
Current: -8.33
During the past 7 years, the highest EV-to-EBITDA of Taysha Gene Therapies was -0.07. The lowest was -37.37. And the median was -4.93.
TSHA's EV-to-EBITDA is ranked worse than 100% of 403
companies
in the Biotechnology industry
Industry Median: 13.21
vs TSHA: -8.33
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Taysha Gene Therapies's PE Ratio (TTM) for today is calculated as:
Taysha Gene Therapies's share price for today is $5.02.
Taysha Gene Therapies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.420.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Taysha Gene Therapies EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Taysha Gene Therapies's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Taysha Gene Therapies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taysha Gene Therapies EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Taysha Gene Therapies's EV-to-EBITDA falls into.
Taysha Gene Therapies's current Enterprise Value is $1,236.99 Mil.
Taysha Gene Therapies's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-148.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taysha Gene Therapies (TSHA) has a EV-to-EBITDA of -8.33 as of Sep. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Taysha Gene Therapies. According to the industry distribution chart, Taysha Gene Therapies ranks #999999 out of 403 companies in the Biotechnology industry.
Is Taysha Gene Therapies' EV-to-EBITDA too high?
Taysha Gene Therapies' current EV-to-EBITDA is -8.33. Based on the distribution chart, Taysha Gene Therapies ranks #999999 out of 403 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Taysha Gene Therapies has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taysha Gene Therapies' EV-to-EBITDA compare to KARD and GHRS?
According to the Biotechnology industry distribution chart, Taysha Gene Therapies ranks #999999 out of 403 companies for EV-to-EBITDA. This places Taysha Gene Therapies in the lower half of its industry. The industry median EV-to-EBITDA is 13.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.21, based on 403 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Taysha Gene Therapies. For the Biotechnology industry, the median EV-to-EBITDA is 13.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taysha Gene Therapies's current EV-to-EBITDA is -8.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taysha Gene Therapies stock overvalued right now?
Based on GuruFocus' analysis, Taysha Gene Therapies (TSHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.53, compared to a current price of $5.02 — trading 847.2% above its estimated fair value. The current EV-to-EBITDA is -8.33. Taysha Gene Therapies' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Taysha Gene Therapies (TSHA), the current EV-to-EBITDA is -8.33 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taysha Gene Therapies (TSHA) Overvalued in 2026?
Based on GuruFocus' analysis, Taysha Gene Therapies stock appears to be overvalued.
The current stock price of $5.02 is trading 847.2% above its estimated GF Value™ of $0.53.
GuruFocus considers Taysha Gene Therapies to be Significantly Overvalued.
Key valuation signals for TSHA:
EV-to-EBITDA: -8.33
GF Value™: $0.53 vs. price of $5.02 (847.2% above fair value)
No single metric tells the full story. See the TSHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
33GF Score
Get the complete analysis for TSHA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSHA has been successfully added to your 
